Invacare stock blooms in April, gaining 4-1/4 points to lead O-T-C Index.
This article was originally published in The Gray Sheet
Executive Summary
INVACARE STOCK STORMS AHEAD 4-1/4 POINTS TO 39-1/2 IN APRIL, advancing for the third consecutive month. The issue, the largest point gainer in April among the 40 O-T-C issues tracked by "The Gray Sheet," realized most of its 12.1% increase following the company's April 20 release of strong first quarter sales and earnings figures.You may also be interested in...
Novartis Targets Ten Indications For Cosentyx
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Zydus Cadila Strides Ahead With NASH Filing In India
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
Interview: Double Delight For ImmuPharma's Dimitriou
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: